High salt intake: a cause of blood pressure-independent left ventricular hypertrophy?

Michel Burnier, Olivier Phan and Qing Wang

Division of Nephrology, Department of Medicine and University of Lausanne, Lausanne, Switzerland

Keywords: blood pressure; cardiac hypertrophy; potassium; sodium

Introduction

Left ventricular hypertrophy (LVH) is a frequent and well-recognized consequence of a chronically elevated blood pressure (BP). Several studies have demonstrated that LVH is an independent cardiovascular risk factor, associated with an increased likelihood to develop cardiovascular complications such as congestive heart failure, sudden cardiac death, coronary heart disease and stroke [1,2]. Conversely, an aggressive treatment of hypertension can prevent and reverse LVH and reduce the incidence of cardiovascular events [3,4].

Non-haemodynamic factors leading to LVH

If BP is definitively the major trigger for the development of cardiac hypertrophy in hypertension, left ventricular mass may be affected by several other non-haemodynamic factors which may also play an important role in the pathophysiology of LVH, as listed in Table 1. Factors such as gender, age, race, obesity, alcohol consumption, catecholamines, ANP, aldosterone and angiotensin II and genetic factors (polymorphism of ACE) have all been considered as BP-independent determinants of left ventricular structure. However, in clinical conditions, it is often difficult to demonstrate that the effect of these factors is really independent of BP, because small but long-standing changes in BP, which may contribute to the development of LVH may be missed, such as for example, nighttime increases in BP. Indeed, the discrimination between normotension and hypertension is arbitrary and a loss of the normal nocturnal decline in BP has been associated with an increased incidence of LVH [5]. Similarly, an excessive rise in BP may induce LVH in subjects who participate in vigorous but unsustained exercises.

Experimental studies in transgenic mice have sometimes provided good evidence that some of these factors induce cardiac hypertrophy, independently of changes in systemic BP. For example, the over-expression of angiotensinogen in cardiomyocytes leads to an increased production of angiotensin II limited to the heart with normal plasma levels [6]. Interestingly, these transgenic mice develop a marked cardiac hypertrophy in the absence of systemic hypertension and the increase in cardiac mass could be prevented by the administration of a blocker of the angiotensin II AT1 receptor [6]. In another transgenic mice model, inactivation of the guanylyl-cyclase-A gene selectively in the heart has been found to exhibit a mild cardiac hypertrophy, a marked increase in mRNA expression of cardiac hypertrophy markers, but a 7–10 mmHg lower BP than control mice [7]. In some experiments, a regression of LVH was found without a decrease in BP [8,9]. For example, non-selective blockade of endothelin receptors with bosentan has been found to lower cardiac hypertrophy without lowering BP [8]. A similar observation was made with the inhibition of the transcription nuclear factor (NF)-kB in spontaneously hypertensive rats [9]. Taken together, these experimental data suggest that there are definite mechanisms which contribute to the development of cardiac hypertrophy independently of BP, but their role in humans remains to be demonstrated.

Does sodium have a role in the development of LVH?

There is also increasing evidence that a high salt intake may have deleterious effects on the cardiovascular system and lead to the development of cardiac and vascular hypertrophy, independently or in addition to its effect on BP [10–12]. However, once again, it is difficult to ascertain whether the impact of the high sodium intake on cardiac mass or vascular...
renin activity and a 100-fold higher plasma renin gene mice exhibit a 10-fold higher plasma difference between these two strains is that the two-
mental data.

The evidence is based on clinical and experi-
þþþ
þ
NF-kB
Parathyroid hormone
Aldosterone
þ
Catecholamines
þ
ANP
þ
Angiotensin II
þþ
þ
Hypokalaemia
þ
Angiotensin II
þ
ANP
þ
Catecholamines
þ
Aldosterone
þ
Parathyroid hormone
þ
NF-kB
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
þ
pathophysiology of cardiac hypertrophy, as correction of the hypokalaemia can prevent the development of cardiac hypertrophy without affecting BP [18]. These data suggest that there might be an interaction between the high-salt intake and the mineralocorticoid-induced loss of potassium to trigger hypertrophic factors leading to cardiac hypertrophy. Yet, other factors may contribute to the development of LVH in the mineralocorticoid-salt-induced model, including the alkalosis itself and the development of hypomagnesaemia, which has also been reported to accompany mineralocorticoid excess and to interact negatively on heart function with the development of hypokalaemia [19].

What is the normal BP in mice with cardiac hypertrophy?

The development of cardiac hypertrophy in the presence of a so-called ‘normal’ BP might raise the question of the normality of BP. One could postulate that there is a resetting of the BP/cardiac hypertrophic-response relationship and that in this situation a lower BP could perhaps prevent the occurrence of cardiac hypertrophy. To test this hypothesis, we recently treated normotensive DOCA/salt mice with a calcium channel blocker, in order to lower their ‘normal’ BP and to assess the impact of lower BP on cardiac hypertrophy. To our surprise, reducing BP in these mice was associated with a reduction in cardiac mass, as shown in Figure 2 [20]. These results would thus suggest that there is indeed a resetting and that in the presence of LVH, one should perhaps aim at a lower BP.

Conclusions

LVH is an independent risk factor for the development of cardiovascular complications in hypertensive patients. Although BP is the major trigger for the development of LVH, several non-haemodynamic factors should also be taken into account, including sodium and potassium intake. Recent animal data have indeed suggested that a high sodium intake is a crucial cofactor contributing to the pathophysiology of cardiac hypertrophy, particularly in situations of mineralocorticoid excess. These observations further emphasize the importance of non-pharmacological recommendations in the management of hypertensive patients, in order to prevent target organ damages.

Conflict of interest statement. None declared.

References


16. Wang Q, Burnier M. Sodium modulates the mineralocorticoid-induced cardiac and renal hypertrophy independently of blood pressure in one-renin gene mice. *J Hypertension* 2004; 22 [Suppl. 1]: S10 (abstract)


Received for publication: 17.3.07
Accepted in revised form: 29.4.07

---

**A primer on iron therapy**

Liliana Schaefer¹ and Roland M. Schaefer²

¹Institute of Pharmacology and Toxicology, University of Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt and
²Department of Medicine, University of Muenster, Albert-Schweitzer-Str 33, 48149 Muenster, Germany

**Keywords:** Chronic kidney disease; renal anaemia; erythropoiesis-stimulating agents (ESA); intravenous iron therapy; anaphylactoid reactions

---

**Introduction**

Iron deficiency is a frequent complication in patients with chronic kidney disease (CKD). Major causes are reduced dietary intake, impaired absorption, chronic blood loss, inflammatory or infectious comorbidity and increased requirements during correction of renal anaemia with erythropoiesis-stimulating agents (ESA).

---

Correspondence and offprint requests to: Roland M. Schaefer, MD, Department of Medicine, University of Muenster, Albert-Schweitzer-Str. 33, 48149 Muenster, Germany. Email: schaefer@uni-muenster.de

Inadequate iron stores with reduced availability of iron to the bone marrow are the main cause of hyporesponsiveness to ESA treatment. Thus, in the vast majority of haemodialysis patients, intravenous iron is used in combination with ESA to treat renal anaemia. Optimal iron management, therefore, includes the monitoring of iron status and the supplementation of adequate amounts of iron, to maintain haemoglobin levels at target in a cost-effective manner [1].

**Monitoring iron status**

**Ferritin**

Serum ferritin is a parameter of iron storage in the reticuloendothelial system. In subjects without kidney disease, a value below 15 ng/ml indicates absolute iron deficiency [2]. In CKD patients, absolute iron